Geron Publishes Analysis Of IMbark Phase 2 In Annals Of Hematology
Reuters 04:52 PM ET October 11, 2021
*GERON ANNOUNCES PUBLICATION OF ANALYSES COMPARING REAL WORLD DATA TO IMBARK PHASE 2 IN ANNALS OF HEMATOLOGY. *GERON CORP- ANALYSES SUGGEST SURVIVAL BENEFIT ASSOCIATED WITH IMETELSTAT TREATMENT IN COMPARISON TO BEST AVAILABLE THERAPY. *GERON CORP- OVERALL SURVIVAL IS PRIMARY ENDPOINT FOR ONGOING PHASE 3 CLINICAL TRIAL IN REFRACTORY MF.
View Full Story in Latest Stories and Headlines for Geron Corp.
You are receiving this email notification because you created this alert on your account. This alert is based on third-party vendor data, the accuracy of which is not warranted. Please do not respond to this email address. This message is for information purposes only. Please understand that email is not secure and should not be used for investment-related questions.
Market Data 
Markets 
AI
